Astrazeneca plc ADR (NASDAQ: AZN)’s stock price has plunge by 0.03relation to previous closing price of 69.55. Nevertheless, the company has seen a 2.93% surge in its stock price over the last five trading sessions. accessnewswire.com reported 2025-04-24 that VANCOUVER, BC / ACCESS Newswire / April 24, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN: A3EKSZ) (“Onco” or the “Company”) is pleased to announce that its wholly owned subsidiary, Inka Health Corp. (“Inka Health”), signed a new analytical work contract[1] with AstraZeneca Canada (“AstraZeneca”) on March 20, 2025 to support the next phase of real-world evidence (RWE) research and scientific dissemination. The Company perceives this renewed engagement as a meaningful signal of confidence in Inka Health’s capacity to support drug evaluation, submission strategies, and evidence planning within Canada’s regulatory framework.
Is It Worth Investing in Astrazeneca plc ADR (NASDAQ: AZN) Right Now?
Astrazeneca plc ADR (NASDAQ: AZN) has a higher price-to-earnings ratio of 30.87x compared to its average ratio, The 36-month beta value for AZN is at 0.41. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 5 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for AZN is 3.10B, and currently, shorts hold a 0.20% of that float. The average trading volume for AZN on April 28, 2025 was 6.06M shares.
AZN’s Market Performance
AZN stock saw a decrease of 2.93% in the past week, with a monthly decline of -4.33% and a quarterly a decrease of 0.74%. The volatility ratio for the week is 1.78%, and the volatility levels for the last 30 days are 2.77% for Astrazeneca plc ADR (AZN). The simple moving average for the last 20 days is 1.12% for AZN stock, with a simple moving average of -5.68% for the last 200 days.
Analysts’ Opinion of AZN
Many brokerage firms have already submitted their reports for AZN stocks, with Exane BNP Paribas repeating the rating for AZN by listing it as a “Outperform.” The predicted price for AZN in the upcoming period, according to Exane BNP Paribas is $75 based on the research report published on April 15, 2025 of the current year 2025.
AZN Trading at -4.44% from the 50-Day Moving Average
After a stumble in the market that brought AZN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.65% of loss for the given period.
Volatility was left at 2.77%, however, over the last 30 days, the volatility rate increased by 1.78%, as shares sank -4.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.53% lower at present.
During the last 5 trading sessions, AZN rose by +2.93%, which changed the moving average for the period of 200-days by -9.26% in comparison to the 20-day moving average, which settled at $68.80. In addition, Astrazeneca plc ADR saw 6.18% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for AZN
Current profitability levels for the company are sitting at:
- 0.18 for the present operating margin
- 0.81 for the gross margin
The net margin for Astrazeneca plc ADR stands at 0.13. The total capital return value is set at 0.13. Equity return is now at value 17.60, with 6.86 for asset returns.
Based on Astrazeneca plc ADR (AZN), the company’s capital structure generated 0.42 points at debt to capital in total, while cash flow to debt ratio is standing at 0.39. The debt to equity ratio resting at 0.74. The interest coverage ratio of the stock is 5.74.
Currently, EBITDA for the company is 17.12 billion with net debt to EBITDA at 1.43. When we switch over and look at the enterprise to sales, we see a ratio of 4.42. The receivables turnover for the company is 4.17for trailing twelve months and the total asset turnover is 0.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.93.
Conclusion
In conclusion, Astrazeneca plc ADR (AZN) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
